Delving into the Latest Updates on Ibuprofen/Codeine Phosphate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

洛芬待因片, Boots Ibuprofen and Codeine, Burana

+ [3]

Target

COX x Opioid receptors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors), Opioid receptors agonists(Opioid receptors agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Acute PainInflammationModerate pain

Inactive Indication-

Originator Organization

GlaxoSmithKline, Inc.

Active Organization

Reckitt Benckiser (Australia) Pty Ltd.

The Boots Co. Plc

Orion Oyj

+ [2]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

AU (17 Feb 2005),

Acute PainInflammationModerate pain

Regulation-

Login to view timeline

Structure

Molecular FormulaC18H26NO8P

InChIKeyJPGKFBXFEQWCAI-CCLYOLAMSA-N

CAS Registry41444-62-6

View All Structures (2)

以马应龙药业集团股份有限公司研制的洛芬待因缓释胶囊为受试制剂，以Reckitt Benckiser Healthcare (UK) Ltd生产的洛芬待因片为参比制剂，比较两者在空腹、餐后条件下单次给药的药代动力学特点，同时比较两者在空腹条件下多次给药的药代动力学特点，以验证洛芬待因缓释胶囊的缓释作用。观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

The fencodeine sustained-release capsules developed by Mayinglong Pharmaceutical Group Co., Ltd. were used as the test preparation, and the fencodeine tablets produced by Reckitt Benckiser Healthcare (UK) Ltd were used as the reference preparation. The pharmacokinetic characteristics of the two were compared after single administration under fasting and postprandial conditions, and the pharmacokinetic characteristics of the two were compared after multiple administration under fasting conditions to verify the sustained-release effect of the fencodeine sustained-release capsules. The safety of the test preparation and the reference preparation in healthy subjects was observed.

Start Date08 Jun 2022

Sponsor / Collaborator

Mayinglong Pharmaceutical Group Co., Ltd.

NCT01535001 / CompletedNot ApplicableIIT

Structured Non-operative Treatment of Knee Osteoarthritis - a Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up

The purpose of this study is to test whether an algorithm for systematic non-surgical treatment consisting of corrective insoles, neuromuscular training, weight loss, patient education and pharmacological treatment with paracetamol, non steroidal anti inflammatory drugs (NSAIDs) and Pantoprazole provides further improvement in pain, function and quality of life than standard non-surgical treatment (information on the disease and how to treat it) in patients with knee osteoarthritis.
The H1-hypothesis is that the treatment algorithm results in a greater increase in quality of life and functional capacity and greater reduction in pain than standard treatment at the primary endpoint, which is follow-up 12months after the start of the treatment.
See statistical analysis plan available under "Links" for further description of the study.

Start Date01 Feb 2012

Sponsor / Collaborator

Danish Rheumatism Association

NCT01410409 / CompletedNot ApplicableIIT

Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement. A Randomized Controlled Trial of Pain, Physical Function and Quality of Life With 12months Follow-up

The purpose of this study is to test whether surgical insertion of total knee replacement provides further improvement in quality of life, pain and function in addition to an algorithm for systematic non-surgical treatment consisting of corrective insoles, neuromuscular training, weight loss, patient education and pharmacological treatment with paracetamol, NSAIDs and Pantoprazol in patients with knee OA, collectively called the MEDIC-treatment(Medicine Exercise Diet Insoles Cognitive).
The H1-hypothesis is that surgery with insertion of TKR in addition to the MEDIC-treatment results in a greater increase in quality of life and functional capacity and greater reduction in pain than the MEDIC- treatment alone at the primary endpoint, which is follow-up 12months after the start of the treatment.
See statistical analysis plan available under "Links" for further description of the study.

Start Date01 Sep 2011

Sponsor / Collaborator

Bevica Innovation A/S

[+5]

100 Clinical Results associated with Ibuprofen/Codeine Phosphate

Login to view more data

100 Translational Medicine associated with Ibuprofen/Codeine Phosphate

Login to view more data

100 Patents (Medical) associated with Ibuprofen/Codeine Phosphate

Login to view more data

3

Literatures (Medical) associated with Ibuprofen/Codeine Phosphate

01 Sep 2023·Exploratory Research in Clinical and Social Pharmacy

The quality of non-prescription medicine counselling in Finnish pharmacies – a simulated patient study

Article

Author: Alastalo, Niina ; Siitonen, Piia ; Hämeen-Anttila, Katri ; Jyrkkä, Johanna

BackgroundMedication counselling provided by pharmacists is important for ensuring the safe use of medicines.ObjectiveTo assess the quality of non-prescription medicines counselling in Finnish pharmacies.MethodsThree scenarios using simulated patient methodology were conducted: the patient requesting a specific brand name Burana® (ibuprofen, OTC medicine), Pronaxen® (naproxen, behind-the-counter (BTC) medicine) and a nasal spray. The visits were conducted in 146 pharmacies by trained simulated patients. Each pharmacy was visited twice. The quality of counselling was defined as poor (1-2 points), moderate (3-4 points), or high (5-6 points) based on developed scenario-based scoring criteria.ResultsThe total number of conducted visits was 292, of which only 29 received high quality counselling. The quality was high in 20% of the cases for Pronaxen® and in 7% of the cases for Nasal spray scenarios. In the Burana® scenario, counselling quality was high only in 2% of the cases. Patients who requested a nasal spray were often asked questions about their symptoms (93%). In the Pronaxen®-scenario, the most frequently asked questions were related to contraindications and drug interactions (56%). The most often given instructions varied between the scenarios, being follow-up in the Burana® and Nasal spray scenarios (17% and 70%, respectively) and how to use the medicine in the Pronaxen®-scenario (63%).ConclusionsNon-prescription medicine counselling is rarely performed with high quality. However, the quality of counselling depends on the medication in question. There is room to improve medication counselling and the assessment of the necessity and suitability of treatment, especially when a patient requests an OTC pain medicine by its brand name.

01 Aug 2008·Clinical Kidney Journal

Ibuprofen codeine combination precipitating severe hypokalaemia in a patient with pre-existing type 1 renal tubular acidosis

Article

Author: Ter, Adeline ; Soper, Charles ; Vadamalai, Vivek ; Salha, Rami

01 Jan 1988·Journal of International Medical ResearchQ4 · MEDICINE

Bioavailability of Three Commercial Preparations of Ibuprofen 600 mg

Q4 · MEDICINE

ArticleOA

Author: Källström, E. ; Heikinheimo, M. ; Quiding, H.

The pharmacokinetic variables of ibuprofen 600 mg were investigated after administration of Brufen and compared to administration of Burana and Ibumetin. The investigation was carried out as a randomized single-dose crossover study in 17 healthy volunteers. The mean maximum plasma concentrations of ibuprofen were 58, 45 and 54 μg/ml after administration of Brufen, Burana and Ibumetin, respectively, the time to reach this being 1.4, 2.1 and 1.6 h, respectively, after administration. The differences between Brufen and Burana were significant. The relative bioavailability was very similar between Brufen and Burana but about 8% lower for Ibumetin and this difference between Brufen and Ibumetin was significant. Thus, different brands of ibuprofen may not be pharmacokinetically interchangeable and the results show that Brufen is superior to either Burana or Ibumetin when considering both the rate and extent of absorption. These findings are clinically interesting since a high and early plasma concentration of ibuprofen seems to be related to increased analgesic efficacy.

100 Deals associated with Ibuprofen/Codeine Phosphate

Login to view more data

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Pain	AU	Reckitt Benckiser (Australia) Pty Ltd.	17 Feb 2005
Inflammation	AU	Reckitt Benckiser (Australia) Pty Ltd.	17 Feb 2005
Moderate pain	AU	Reckitt Benckiser (Australia) Pty Ltd.	17 Feb 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01535001 (CTgov)	Not Applicable	Pain \| Osteoarthritis, Knee	100	Insoles+paracetamol+Burana+Pantoprazole (MEDIC)	pbrkjikhbi(hjzftimbsl) = jiphvnkyrw apzudritmj (dxcqvtireh, aoejhsbuob - nhtdmqehpa) View more	-	27 Jan 2016
				Information (Standard Treatment)	pbrkjikhbi(hjzftimbsl) = pxkykegvlg apzudritmj (dxcqvtireh, qkowqpsqrc - sggnkeeexo) View more
NCT01410409 (MEDIC, CTgov)	Not Applicable	Pain \| Osteoarthritis, Knee	100	Insoles+Paracetamol+Burana+Pantoprazol (MEDIC)	fobfkzddoz(djctbwipyc) = blsificltt tvluqlyzpt (mcqkcaafon, wwgovhtztr - gsqjvhrvef) View more	-	27 Jan 2016
				Insoles+Paracetamol+Burana+Pantoprazol (MEDIC + TKR)	fobfkzddoz(djctbwipyc) = fgodewmeng tvluqlyzpt (mcqkcaafon, elogctjiic - yewknwjpte) View more